CONTROLLED CLINICAL STUDIES WITH AN ANTIDOTE AGAINST THE UROTOXICITY OF OXAZAPHOSPHORINES - PRELIMINARY-RESULTS

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (3) , 501-505
Abstract
A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide. Eleven patients received mesnum i.v. and 9 patients received a standard prophylaxis. The frequency of microhematuria was significantly lower in the patients receiving mesnum. A slight microhematuria was observed in 1 patient. With the standard prophylaxis, all 9 patients receiving single-agent therapy with ifosfamide or cyclophosphamide had hematuria and 3 of these had macrohematuria. According to the available results, a daily mesnum dose of 60% (wt/wt) of the ifosfamide or cyclophosphamide dose is recommended. This dose should be divided into 3 equal fractions. The 1st administration should be given concurrently with the cytostatic agent and the subsequent 2 administrations at 4 and 8 h after administration of the cytostatic agent. Significantly higher doses of mesnum (e.g., 133% of the cyclophosphamide or ifosfamide doses) lead to gastrointestinal disorders, which are easily reversible.

This publication has 0 references indexed in Scilit: